Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICOBOO COVID-19 booster vaccine strategy trial
ACTRN12622000238774Phase 4Active, not recruiting
- Sponsor
- The Kids Research Institute Australia
- Start
- Mar 2022
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Comirnaty JN.1, Spikevax JN.1 and Nuvaxovid JN.1 (3 arms). Primary endpoint: Serum concentrations of SARS-CoV-2 anti-spike IgG. Started Mar 2022; status: active, not recruiting.
02
Drugs
bretovameranJN.1-adapted COVID-19 vaccineNuvaxovid JN.1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12622000238774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000238774.